25 May 2013
Keywords: cpmp, backs, avonex, early-stage, ms, biogen, multiple
Article | 11 March 2002
Biogen's multiple sclerosis drug Avonex (interferon beta-1a) has beenrecommended for approval by the European Union's Committee for
Proprietary Medicinal ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 March 2002
25 March 2002
24 May 2013
© 2013 thepharmaletter.com